Immunocore Holdings plc Interest Expense
Immunocore Holdings plc (IMCR) reported Interest Expense of $3.24 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-08.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-05-08
- Immunocore Holdings plc interest expense for the quarter ending 2024-03-31 was $3.24M, a 159.12% increase year-over-year.
- Immunocore Holdings plc interest expense for the quarter ending 2023-03-31 was $1.25M.
- Immunocore Holdings plc interest expense for fiscal 2023 was $5.15M, a 4.71% decline from fiscal 2022.
- Immunocore Holdings plc interest expense for fiscal 2022 was $5.41M, a 2.94% decline from fiscal 2021.
- Immunocore Holdings plc interest expense for fiscal 2021 was $5.57M.
| Period end | Interest Expense 3 month | Interest Expense 12 month |
|---|---|---|
| 2024-03-31 | $3.24M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $5.15M 10-K · filed 2024-02-28 | |
| 2023-03-31 | $1.25M 10-Q · filed 2024-05-08 | |
| 2022-12-31 | $5.41M 10-K · filed 2024-02-28 | |
| 2021-12-31 | $5.57M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |